Literature DB >> 21220319

Unexpected protective role for Toll-like receptor 3 in the arterial wall.

Jennifer E Cole1, Tina J Navin, Amanda J Cross, Michael E Goddard, Lena Alexopoulou, Anuja T Mitra, Alun H Davies, Richard A Flavell, Marc Feldmann, Claudia Monaco.   

Abstract

The critical role of Toll-like receptors (TLRs) in mammalian host defense has been extensively explored in recent years. The capacity of about 10 TLRs to recognize conserved patterns on many bacterial and viral pathogens is remarkable. With so few receptors, cross-reactivity with self-tissue components often occurs. Previous studies have frequently assigned detrimental roles to TLRs, in particular to TLR2 and TLR4, in immune and cardiovascular disease. Using human and murine systems, we have investigated the consequence of TLR3 signaling in vascular disease. We compared the responses of human atheroma-derived smooth muscle cells (AthSMC) and control aortic smooth muscle cells (AoSMC) to various TLR ligands. AthSMC exhibited a specific increase in TLR3 expression and TLR3-dependent functional responses. Intriguingly, exposure to dsRNA in vitro and in vivo induced increased expression of both pro- and anti-inflammatory genes in vascular cells and tissues. Therefore, we sought to assess the contribution of TLR3 signaling in vivo in mechanical and hypercholesterolemia-induced arterial injury. Surprisingly, neointima formation in a perivascular collar-induced injury model was reduced by the systemic administration of the dsRNA analog Poly(I:C) in a TLR3-dependent manner. Furthermore, genetic deletion of TLR3 dramatically enhanced the development of elastic lamina damage after collar-induced injury. Accordingly, deficiency of TLR3 accelerated the onset of atherosclerosis in hypercholesterolemic ApoE(-/-) mice. Collectively, our data describe a protective role for TLR signaling in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220319      PMCID: PMC3038746          DOI: 10.1073/pnas.1018515108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

Authors:  Alan D Lopez; Colin D Mathers; Majid Ezzati; Dean T Jamison; Christopher J L Murray
Journal:  Lancet       Date:  2006-05-27       Impact factor: 79.321

2.  Modulation of atherosclerosis in mice by Toll-like receptor 2.

Authors:  Adam E Mullick; Peter S Tobias; Linda K Curtiss
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

Review 3.  Innate immunity: the virtues of a nonclonal system of recognition.

Authors:  R Medzhitov; C A Janeway
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

4.  Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells.

Authors:  Xin Yang; Vanishree Murthy; Kelly Schultz; Jeffrey B Tatro; Katherine A Fitzgerald; Debbie Beasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-16       Impact factor: 4.733

5.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Authors:  M F Roelofs; L A B Joosten; S Abdollahi-Roodsaz; A W T van Lieshout; T Sprong; F H van den Hoogen; W B van den Berg; T R D J Radstake
Journal:  Arthritis Rheum       Date:  2005-08

6.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis.

Authors:  Marco Prinz; Folker Garbe; Hauke Schmidt; Alexander Mildner; Ilona Gutcher; Karina Wolter; Matthias Piesche; Roland Schroers; Elisabeth Weiss; Carsten J Kirschning; Christian D P Rochford; Wolfgang Brück; Burkhard Becher
Journal:  J Clin Invest       Date:  2006-01-26       Impact factor: 14.808

7.  Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.

Authors:  Noritaka Koga; Jun-ichi Suzuki; Hisanori Kosuge; Go Haraguchi; Yasuyuki Onai; Hideki Futamatsu; Yasuhiro Maejima; Ryo Gotoh; Hitoshi Saiki; Fumihiko Tsushima; Miyuki Azuma; Mitsuaki Isobe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-16       Impact factor: 8.311

8.  Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation.

Authors:  R F Booth; J F Martin; A C Honey; D G Hassall; J E Beesley; S Moncada
Journal:  Atherosclerosis       Date:  1989-04       Impact factor: 5.162

9.  Virus-induced atherosclerosis.

Authors:  C G Fabricant; J Fabricant; M M Litrenta; C R Minick
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

10.  Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators.

Authors:  Malika Bsibsi; Carla Persoon-Deen; Ronald W H Verwer; Sonja Meeuwsen; Rivka Ravid; Johannes M Van Noort
Journal:  Glia       Date:  2006-05       Impact factor: 7.452

View more
  67 in total

Review 1.  Microbial Nucleic Acid Sensing in Oral and Systemic Diseases.

Authors:  K E Crump; S E Sahingur
Journal:  J Dent Res       Date:  2015-10-05       Impact factor: 6.116

Review 2.  Therapeutic Transdifferentiation: A Novel Approach for Ischemic Syndromes.

Authors:  Jennifer P Connell; Santhisri Kodali; John P Cooke
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Jul-Sep

3.  TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.

Authors:  Shao Liang; Ma Aiqun; Li Jiwu; Zhang Ping
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  Activation of Toll-like receptor 3 increases mouse aortic vascular smooth muscle cell contractility through ERK1/2 pathway.

Authors:  Trevor Hardigan; Kathryn Spitler; Takayuki Matsumoto; Maria Alicia Carrillo-Sepulveda
Journal:  Pflugers Arch       Date:  2015-03-01       Impact factor: 3.657

Review 5.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

6.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

7.  Toll in the vessel wall--for better or worse?

Authors:  Göran K Hansson; Anna M Lundberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-03       Impact factor: 11.205

8.  An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux.

Authors:  Mark A Gillespie; Elizabeth S Gold; Stephen A Ramsey; Irina Podolsky; Alan Aderem; Jeffrey A Ranish
Journal:  EMBO J       Date:  2015-03-09       Impact factor: 11.598

9.  Impaired innate immune signaling due to combined Toll-like receptor 2 and 4 deficiency affects both periodontitis and atherosclerosis in response to polybacterial infection.

Authors:  Sasanka S Chukkapalli; Sriram Ambadapadi; Kyle Varkoly; Jessica Jiron; Jose Ignacio Aguirre; Indraneel Bhattacharyya; Laurence M Morel; Alexandra R Lucas; Lakshmyya Kesavalu
Journal:  Pathog Dis       Date:  2018-11-01       Impact factor: 3.166

10.  Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.

Authors:  Michalis Mastri; Zaeem Shah; Terence McLaughlin; Christopher J Greene; Leah Baum; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.